Effects of Raltegravir or Elvitegravir Resistance Signature Mutations on the Barrier to Dolutegravir Resistance In Vitro

The recently approved HIV-1 integrase strand transfer inhibitor (INSTI) dolutegravir (DTG) (S/GSK1349572) has overall advantageous activity when tested in vitro against HIV-1 with raltegravir (RAL) and elvitegravir (EVG) resistance signature mutations. We conducted an in vitro resistance selection s...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Antimicrob Agents Chemother
Main Authors: Seki, Takahiro, Suyama-Kagitani, Akemi, Kawauchi-Miki, Shinobu, Miki, Shigeru, Wakasa-Morimoto, Chiaki, Akihisa, Erika, Nakahara, Koichiro, Kobayashi, Masanori, Underwood, Mark R., Sato, Akihiko, Fujiwara, Tamio, Yoshinaga, Tomokazu
Formato: Artigo
Idioma:Inglês
Publicado: American Society for Microbiology 2015
Assuntos:
Antiviral Agents
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4394817/
https://ncbi.nlm.nih.gov/pubmed/25691633
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.04844-14
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares